A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

ClinicalTrials.gov ID: NCT07280013

Public ClinicalTrials.gov record NCT07280013. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 9, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1B, Open-label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Study identification

NCT ID: NCT07280013
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: C4 Therapeutics, Inc.; Industry
Enrollment: 60 participants

Conditions and interventions

Conditions

Multiple Myeloma (MM)

Interventions

Cemsidomide Drug
Elranatamab Biological

Drug · Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 5, 2026
Primary completion: Nov 30, 2028
Completion: May 31, 2029
Last update posted: Apr 16, 2026

2026 – 2029

United States locations

U.S. sites: 16
U.S. states: 15
U.S. cities: 16

Facility	City	State	ZIP	Site status
Banner MD Anderson Cancer Center	Gilbert	Arizona	85234	Not yet recruiting
UCLA Health, Jonsson Comprehensive Cancer Center	Santa Monica	California	90404	Not yet recruiting
Tampa General Hospital	Tampa	Florida	33606	Not yet recruiting
Winship Cancer Institute, Emory University	Atlanta	Georgia	30322	Recruiting
Loyola University Medical Center	Maywood	Illinois	60153	Not yet recruiting
Indiana University	Indianapolis	Indiana	46202	Not yet recruiting
Norton Cancer Institute St. Matthews	Louisville	Kentucky	40207	Not yet recruiting
University of Maryland Greenbaum Comprehensive Cancer Center	Baltimore	Maryland	21201	Not yet recruiting
START Midwest	Grand Rapids	Michigan	49546	Recruiting
University of Nebraska	Omaha	Nebraska	68105	Not yet recruiting
Dartmouth-Hitchcock Medical Center	Lebanon	New Hampshire	03756	Not yet recruiting
Perlmutter Cancer Center at NYU Langone Hospital	Brooklyn	New York	11203	Not yet recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10021	Not yet recruiting
Duke Cancer Center	Durham	North Carolina	27710	Not yet recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Not yet recruiting
Huntsman Cancer Institute, University of Utah	Salt Lake City	Utah	84112	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07280013, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 16, 2026 · Synced May 9, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07280013 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →